Core Viewpoint - The collaboration between 旺山旺水-B and 先声药业 aims to accelerate the clinical development and commercialization of VV116 for new indications, specifically targeting RSV and HMPV infections in Greater China [1][2]. Group 1: Licensing Agreement - 旺山旺水-B has entered into a licensing agreement with 先声药业 for exclusive rights to develop VV116 for RSV and HMPV infections in Greater China [1]. - The partnership leverages the strengths of both companies in research, production, and commercialization to benefit more patients [1]. Group 2: Product Overview - VV116 is an oral nucleoside prodrug that received conditional approval from the National Medical Products Administration (NMPA) in January 2023 for treating mild to moderate COVID-19, with plans for full approval by January 2025 [1]. - VV116 has shown broad-spectrum antiviral activity against various RNA viruses, including RSV, demonstrating good inhibition effects [1]. Group 3: Clinical Trials and Safety - A Phase II clinical trial for VV116 as a treatment for RSV in infants has been completed, leading to its designation as a breakthrough therapy by NMPA [2]. - Preclinical studies indicate significant antiviral effects of VV116 in vitro and in animal models, along with improvements in lung pathology [2]. - Clinical pharmacokinetic studies show good oral absorption and linear pharmacokinetics, with no significant impact from infant formula on its main metabolites [2]. - Overall safety of VV116 in clinical studies is reported to be good, with no severe adverse events noted [2].
旺山旺水-B(02630)与先声药业(02096)就VV116新适应症订立许可协议